New SGLT2 Inhibitors (Kidney & Heart) treatments in trials

Empagliflozin, Dapagliflozin — glycaemic control, heart failure & chronic kidney disease. Track the treatments still in clinical testing and see which are closest to an FDA decision.

74Closest to approval (Phase 3)

69Mid-stage (Phase 2)

59Early stage (Phase 1)

872Total recruiting

In one line

872 sglt2 inhibitors (kidney & heart) trials are recruiting right now, 74 of them in Phase 3 — the stage immediately before an FDA decision.

Recruiting now

Twelve of the currently recruiting studies. Open one for a plain-English summary of who it is for and what it involves.

NCT07512934RecruitingAssessment of Pancreatic Dysfunction in Patients With Type 2 DiabetesSponsorWest Kazakhstan Marat Ospanov Medical UniversityEnrolling310Summary NCT04874012Phase 2RecruitingTaurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 DiabetesSponsorHospital de Clinicas de Porto AlegreEnrolling94Summary NCT06571500RecruitingGrowth Hormone Resistance of Beta-cells in People With a Family History of Type 2 DiabetesSponsorUniversity of Missouri-ColumbiaEnrolling30Summary NCT04579900NARecruitingDissecting Host-microbiome Modifiers of Type 2 Diabetes RiskSponsorLaval UniversityEnrolling40Summary NCT07790081NARecruitingIntegrating Educational Videos Into Skills-Based Nutrition Programs to Reduce Type 2 Diabetes Risk in PeelSponsorUniversity of TorontoEnrolling45Summary NCT07392437NARecruitingPrevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and Identification of Its Associated Factors.SponsorCentre Hospitalier Universitaire de NiceEnrolling290Summary NCT06906640NARecruitingImplementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)SponsorDuke UniversityEnrolling212Summary NCT07513168Phase 4RecruitingLow-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani AdultsSponsorAsian Institute Of Medical SciencesEnrolling60Summary NCT07159282Phase 4RecruitingA Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot UlcersSponsorApplied Biologics, LLCEnrolling60Summary NCT07812623NARecruitingA Twelve-Week Pilot Study Evaluating the Usability and Preliminary Effects of SugarVita 2.0 in Adults With Type 2 DiabetesSponsorMaxima Medical CenterEnrolling30Summary NCT07446179NARecruitingBlood Glucose Response to Test Foods Containing Brewer's Spent GrainSponsorUniversidad Católica del UruguayEnrolling20Summary NCT06220773Phase 3RecruitingA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination TherapySponsorBoryung Pharmaceutical Co., LtdEnrolling276Summary

View all 872 on ClinicalTrials.gov

Already approved for this area

SGLT2 Inhibitors

Jardiance, Farxiga, Invokana, Steglatro — approved products with their NDC records and billing codes.

Open the class

Every NDC in this class

The FDA registry filtered to sglt2 inhibitors, with packaging and 11-digit billing conversions.

Search the directory

Loading the trial explorer…